Company news

PepGen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors

November 14, 2023

PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

November 7, 2023

PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

October 11, 2023

PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology

September 26, 2023

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences

September 5, 2023

PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1

September 5, 2023

PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference

August 31, 2023

PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

August 7, 2023

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

June 12, 2023

PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

May 29, 2023

PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy

May 17, 2023

PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 10, 2023

PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference

May 3, 2023

PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting

April 16, 2023

PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023

PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments

March 22, 2023

PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference

March 21, 2023

PepGen to Participate in the Stifel 2023 CNS Days Conference

March 20, 2023

PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call

March 15, 2023

PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference

March 12, 2023

PepGen to Participate in the SVB Securities Global Biopharma Conference

February 8, 2023

PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

December 6, 2022

PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates

November 13, 2022

PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 9, 2022

PepGen to Participate in the Stifel 2022 Healthcare Conference

November 7, 2022

PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress

October 12, 2022

PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

September 27, 2022

PepGen Appoints Habib Dable to Board of Directors

September 21, 2022

PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

August 11, 2022

PepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board

July 21, 2022

PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments

June 15, 2022

PepGen Announces Pricing of Initial Public Offering

May 4, 2022

← Newer news releases

Calls

Decks

The 5 newest of 17 decks. Every deck is listed under its year.